## CITATION REPORT List of articles citing

Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction

DOI: 10.1161/circheartfailure.113.001229 Circulation: Heart Failure, 2014, 7, 935-44.

Source: https://exaly.com/paper-pdf/59557898/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
325	Noninvasive Hemodynamic Monitoring for Heart Failure: A New Era of Heart Failure Management. <b>2015</b> , 1, 57-64	
324	Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. <b>2015</b> , 30, 250-8	18
323	Chronic heart failure: what does the horizon look like?. <b>2015</b> , 30, 344-53	4
322	Evolution from electrophysiologic to hemodynamic monitoring: the story of left atrial and pulmonary artery pressure monitors. <b>2015</b> , 6, 271	9
321	Acute Heart Failure and Implantable Cardiac Devices in the Acute Care Setting. <b>2015</b> , 3, 74-79	
320	Implantable Hemodynamic Monitoring in Ambulatory Heart Failure: Who, When, Why, How?. <b>2015</b> , 17, 113	2
319	Current Technology to Maximize Cardiac Resynchronization Therapy Benefit for Patients With Symptomatic Heart Failure. <b>2015</b> , 26, 329-40; quiz 341-2	1
318	[Implantable hemodynamic monitoring devices]. <b>2015</b> , 40, 966-71	О
317	The role of implantable hemodynamic monitors to manage heart failure. <b>2015</b> , 11, 183-9	5
316	Left Atrial Decompression Using Unidirectional Left-to-Right Interatrial Shunt: Initial Experience in Treating Symptomatic Heart Failure With Preserved Ejection Fraction With the W-Wave Device. <b>2015</b> , 8, 870-872	10
315	Transcatheter Structural Heart Interventions for the Treatment of Chronic Heart Failure. <b>2015</b> , 8, e001943	7
314	Pulmonary congestion at rest and abnormal ventilation during exercise in chronic systolic heart failure. <b>2015</b> , 4,	4
313	Team-Based Care for Outpatients with Heart Failure. <b>2015</b> , 11, 379-405	19
312	Pulmonale Hypertonie bei Lungen- und Linksherzerkrankungen. <b>2015</b> , 12, 410-416	2
311	Heart failure with preserved ejection fraction in the elderly: scope of the problem. 2015, 83, 73-87	94
310	Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect?. <b>2015</b> , 12, 215-22	32
309	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. <b>2015</b> , 373, 2314-24	331

308	Heart failure with preserved ejection fraction: uncertainties and dilemmas. 2015, 17, 665-71	97
307	Management of heart failure with preserved ejection fraction: a review. <b>2015</b> , 37, 2186-98	25
306	Differential diagnosis and clinical management of diastolic heart failure: current best practice. <b>2016</b> , Volume 7, 117-135	0
305	Treatment of Heart Failure With Reduced Ejection Fraction-Recent Developments. <b>2016</b> , 23, e531-49	1
304	Remote heart function monitoring: role of the CardioMEMS HF System. <b>2016</b> , 17, 518-23	6
303	First implantable hemodynamic monitoring device placement in single ventricle fontan anatomy. <b>2016</b> , 88, 248-52	8
302	After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. 2016, 37, 3135-3140	18
301	Right ventricular dysfunction and pulmonary hypertension in heart failure with preserved ejection fraction. <b>2016</b> , 18, 1488-1490	2
300	Acute decompensated heart failure (ADHF): A comprehensive contemporary review on preventing early readmissions and postdischarge death. <b>2016</b> , 223, 1035-1044	19
299	Spatial Orientation and Morphology of the Pulmonary Artery: Relevance to Optimising Design and Positioning of a Continuous Pressure Monitoring Device. <b>2016</b> , 9, 239-248	2
298	The use of micro-electro mechanical systems in vascular monitoring: implications for clinical use. <b>2016</b> , 13, 831-7	2
297	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <b>2016</b> , 18, 1472-1487	128
296	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. <b>2016</b> , 68, 368-78	148
295	Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure. <b>2016</b> , 30, 599-609	46
294	Heart Failure with Preserved Ejection Fraction. <b>2016</b> , 375, 1868-1877	267
293	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. <b>2016</b> , 68, 2217-2228	157
292	Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions.  Circulation: Heart Failure, <b>2016</b> , 9,	50
291	Fluid status telemedicine alerts for heart failure: a randomized controlled trial. <b>2016</b> , 37, 3154-3163	116

290	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. <b>2016</b> , 134, 73-90	485
289	Mobile technology and the digitization of healthcare. <b>2016</b> , 37, 1428-38	191
288	Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance.  Circulation: Heart Failure, <b>2016</b> , 9, e002543  7.6	13
287	A systematic review of transitional-care strategies to reduce rehospitalization in patients with heart failure. <b>2016</b> , 45, 100-13	52
286	Cardiovascular Serenade: Listening to the Heart. <b>2016</b> , 87-100	
285	Cap <b>E</b> ulo 13. Novedades en el tratamiento de la falla cardiaca. <b>2016</b> , 23, 55-58	
284	Heart Failure With Preserved Ejection Fraction. <b>2016</b> , 41, 145-88	80
283	Heart Failure Management: The Neural Pathways. 2016,	
282	Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. <b>2016</b> , 387, 453-61	296
281	Left ventricular heart failure and pulmonary hypertension. <b>2016</b> , 37, 942-54	316
280	Short Stay Management of Acute Heart Failure. 2017,	
279	COUNTERPOINT: Should Wireless Pulmonary Artery Hemodynamic Monitoring Be Used to Monitor Patients With Pulmonary Hypertension? No. <b>2017</b> , 152, 16-18	O
278	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	54
277	Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. <b>2017</b> , 135, 1509-1517	81
276	The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. <b>2017</b> , 19, 661-669	24
275	Early Rehospitalization After Prolonged Intensive Care Unit Stay Post Cardiac Surgery: Outcomes and Modifiable Risk Factors. <b>2017</b> , 6,	5
274	Contemporary Approaches to Patients with Heart Failure. <b>2017</b> , 35, 261-271	15
273	Measuring Pulmonary Artery Pressures in Heart Failure: A New Useful Diagnostic Tool?. <b>2017</b> , 135, 1518-1521	4

272	The Role of Implantable Hemodynamic Monitors to Manage Heart Failure. 2017, 35, 273-279		4
271	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	37
270	Pulmonary artery pressure-based telemedicine in heart failure: ready for Europe?. 2017, 19, 670-672		
269	Causes and Predictors of 30-Day Readmissions in Atrial Fibrillation (from the Nationwide Readmissions Database). <b>2017</b> , 120, 399-403		11
268	Epidemiology of heart failure with preserved ejection fraction. <b>2017</b> , 14, 591-602		459
267	Hemodynamic-guided heart-failure management using a wireless implantable sensor: Infrastructure, methods, and results in a community heart failure disease-management program. <b>2017</b> , 40, 170-176		25
266	How Trialists and Pharmaceutical Sponsors Have Failed Us by Thinking That Acute Heart Failure Is a 48-Hour Illness. <b>2017</b> , 120, 505-508		13
265	Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. <b>2017</b> , 10, 233-244		40
264	Heart Failure with Preserved Ejection Fraction in Older Adults. <b>2017</b> , 13, 485-502		38
263	Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy?. <b>2017</b> , 19, 971-973		9
262	Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. <b>2017</b> , 17, 283-298		6
261	Remote Monitoring in Heart Failure: the Current State. <b>2017</b> , 19, 22		4
260	Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice. <b>2017</b> , 69, 2357-2365		105
259	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	13
258	Stepping Out of the Left Ventricle Shadow: Time to Focus on the Left Atrium in Heart Failure With Preserved Ejection Fraction. <b>2017</b> , 10,		23
257	Remote Monitoring to Reduce Heart Failure Readmissions. <b>2017</b> , 14, 40-47		15
256	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. <b>2017</b> , 70, 1875-1886		124
255	The day of the week and acute heart failure admissions: Relationship with acute myocardial infarction, 30-day readmission rate and in-hospital mortality. <b>2017</b> , 249, 292-300		20

254	Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. <b>2017</b> , 5, 763-771	103
253	Use and Disuse of Observational Research: The Case of Remote Monitoring in Heart Failure. <b>2017</b> , 137, 14-19	2
252	[Non-device-based telemonitoring : Toy or tool?]. <b>2017</b> , 28, 287-292	O
251	Heart Failure With Preserved Ejection Fraction: A Perioperative Review. <b>2017</b> , 31, 1820-1830	7
250	Pulmonary Pressure Monitoring for Patients With Heart Failure. <b>2017</b> , 25, 53-58	1
249	[Device-based remote monitoring : Current evidence]. <b>2017</b> , 28, 268-278	1
248	What can we learn from pulmonary function testing in heart failure?. <b>2017</b> , 19, 1222-1229	27
247	Interventional Therapies for Heart Failure in Older Adults. <b>2017</b> , 13, 535-570	2
246	Implantable Hemodynamic Monitoring for Heart Failure Patients. 2017, 70, 389-398	62
245	Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. <b>2017</b> , 10, 322-336	27
244	Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials. <b>2017</b> , 19, 426-433	34
243	Sildenafil, unbridled optimism, and heart failure with preserved ejection fraction. <b>2017</b> , 19, 126-128	1
242	Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial. <b>2017</b> , 19, 652-660	30
241	How to Set Up an HF Monitoring Service. <b>2017</b> , 255-261	
240	Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure. <b>2017</b> ,	
239	Future Diagnostic Strategies Pediatric. 2017, 361-379	
238	A Perspective on Recent Hospital Strategies to Reduce Heart Failure Readmissions and Improve Outcomes. <b>2017</b> , 11, 1	1
237	Long-term impact of intrathoracic impedance findings on survival and heart failure hospitalizations after cardiac resynchronization therapy in ICD Registry patients. <b>2018</b> , 20, 1138-1145	5

## (2018-2018)

236	diagnosis and treatment. <b>2018</b> , 28, 392-400	18
235	Heart failure with preserved ejection fraction: controversies, challenges and future directions. <b>2018</b> , 104, 377-384	53
234	Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review. <b>2018</b> , 20, 28	11
233	Implantable devices for heart failure monitoring and therapy. <b>2018</b> , 23, 935-944	8
232	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <b>2018</b> , 20, 16-37	137
231	The Utility of a Wireless Implantable Hemodynamic Monitoring System in Patients Requiring Mechanical Circulatory Support. <b>2018</b> , 64, 301-308	19
230	Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. 2018, 6, 273-285	78
229	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. <b>2018</b> , 137, 364-375	140
228	Telemonitoring of left-ventricular assist device patients-current status and future challenges. <b>2018</b> , 10, S1794-S1801	18
227	Heart Failure Monitoring. 2018, 453-463	
227	Heart Failure Monitoring. 2018, 453-463  OBSOLETE: Heart Failure Monitoring. 2018,	
		o
226	OBSOLETE: Heart Failure Monitoring. 2018,	0
226	OBSOLETE: Heart Failure Monitoring. 2018, . 2018,	O 2
226 225 224	OBSOLETE: Heart Failure Monitoring. 2018,  . 2018,  Implantable devices to monitor patients with heart failure. 2018, 23, 849-857	
226 225 224 223	OBSOLETE: Heart Failure Monitoring. 2018,  . 2018,  Implantable devices to monitor patients with heart failure. 2018, 23, 849-857  [Telemonitoring and pulmonary artery pressure-guided treatment of heart failure]. 2018, 59, 1041-1053	O
226 225 224 223	OBSOLETE: Heart Failure Monitoring. 2018,  . 2018,  Implantable devices to monitor patients with heart failure. 2018, 23, 849-857  [Telemonitoring and pulmonary artery pressure-guided treatment of heart failure]. 2018, 59, 1041-1053  Setting Up a Heart Failure Program in 2018: Moving Towards New Paradigm(s). 2018, 15, 357-367  Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of	o 3
226 225 224 223 222	OBSOLETE: Heart Failure Monitoring. 2018,  . 2018,  Implantable devices to monitor patients with heart failure. 2018, 23, 849-857  [Telemonitoring and pulmonary artery pressure-guided treatment of heart failure]. 2018, 59, 1041-1053  Setting Up a Heart Failure Program in 2018: Moving Towards New Paradigm(s). 2018, 15, 357-367  Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. 2018, 24, 682-694	3

218	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). <b>2018</b> , 107, 991-1002	20
217	Burden of nursing activities during hemodynamic monitoring of heart failure patients. <b>2018</b> , 47, 304-307	1
216	The Luck of Having a Cardiac Implantable Electronic Device. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e0048947.6	4
215	Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues. <b>2018</b> , 5, 755-763	7
214	Vorhofseptum-Shunt bei schwerer diastolischer Herzinsuffizienz. <b>2018</b> , 18, 39-42	O
213	Chronic heart failure management and remote haemodynamic monitoring. 2018, 104, 1910-1919	6
212	Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. <b>2018</b> , 23, 609-629	19
211	Heart failure with preserved ejection fraction: from mechanisms to therapies. <b>2018</b> , 39, 2780-2792	155
210	Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches. <b>2019</b> , 44, 483-490	9
209	Long-term Prognostic Significance of Admission Tricuspid Regurgitation Pressure Gradient in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction: A Report From the Japanese Real-World Multicenter Registry. <b>2019</b> , 25, 978-985	7
208	Current Role of the CardioMEMS Device for Management of Patients with Heart Failure. <b>2019</b> , 21, 98	3
207	20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology. <b>2019</b> , 32, 1379-1395.e2	6
206	Using Data Science to Predict Readmissions in Heart Failure. <b>2019</b> , 7, 175-183	
205	Economic Impact of Chronic Heart Failure Management in Today@ Cost-Conscious Environment. <b>2019</b> , 11, 1-9	11
204	The Role of Echocardiography in Heart Failure with Preserved Ejection Fraction: What Do We Want from Imaging?. <b>2019</b> , 15, 241-256	15
203	Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials. <b>2019</b> , 487, 54-58	8
202	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e006125	10
201	Heart failure with preserved ejection fraction in elderly. From pathophysiology to treatment: an unresolved problem. <b>2019</b> , 89,	1

## (2020-2019)

200	Heart Failure With Preserved Ejection Fraction In Perspective. <b>2019</b> , 124, 1598-1617	229
199	Does My Patient with Multiple Comorbidities Have Heart Failure with Preserved Ejection Fraction, and Does It Matter?. <b>2019</b> , 32, 424-427	1
198	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <b>2019</b> , 214, 18-27	24
197	Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. <b>2019</b> , 21, 20	19
196	Heart Failure with Preserved Ejection Fraction: Time to Revisit the Stiff Heart. <b>2019</b> , 3, 409-420	1
195	Impact of Hospice and Palliative Care Service Utilization on All-Cause 30-Day Readmission Rate for Older Adults Hospitalized with Heart Failure. <b>2019</b> , 36, 623-629	2
194	An update on the CardioMEMS pulmonary artery pressure sensor. <b>2019</b> , 13, 1753944719826826	14
193	Implantable devices for heart failure monitoring: the CardioMEMSIsystem. 2019, 21, M50-M53	7
192	Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. <b>2019</b> , 40, 689-697	94
191	Rapid right-sided deterioration in heart failure with preserved ejection fraction. <b>2019</b> , 40, 699-702	2
190	Ambulatory Fontan pressure monitoring: Results from the implantable hemodynamic monitor Fontan feasibility cohort (IHM-FFC). <b>2019</b> , 284, 22-27	3
189	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. <b>2019</b> , 6, 62-69	34
188	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. <b>2020</b> , 26, 101-107	14
187	Treatment of Heart Failure with Preserved Ejection Fraction. <b>2020</b> , 568-585	
186	Should We Test for Diastolic Dysfunction? How and How Often?. <b>2020</b> , 13, 297-309	4
185	Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. <b>2020</b> , 13, 245-257	56
184	CardioMEMS, the real progress in heart failure home monitoring. <b>2020</b> , 25, 93-98	3
183	Cardiorenal Syndrome in Heart Failure. <b>2020</b> ,	1

182	When Pulmonary Hypertension Complicates Heart Failure. <b>2020</b> , 16, 53-60	8
181	The Cardiorenal Syndrome in Heart Failure. <b>2020</b> , 16, 81-97	19
180	Heart failure with preserved ejection fraction: Similarities and differences between women and men. <b>2020</b> , 304, 101-108	12
179	Heart failure with preserved ejection fraction: New approaches to diagnosis and management. <b>2020</b> , 43, 145-155	29
178	Contemporary approach to treating heart failure. <b>2020</b> , 30, 507-518	3
177	Remote monitoring of chronic heart failure patients: invasive versus non-invasive tools for optimising patient management. <b>2020</b> , 28, 3-13	15
176	Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes. <b>2020</b> , 142, 1246-1248	
175	Interatrial shunt devices for the treatment of heart failure. <b>2021</b> , 31, 427-432	8
174	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. <b>2020</b> , 36, 977-992	12
173	Gerotechnology for Older Adults With Cardiovascular Diseases: JACC State-of-the-Art Review. <b>2020</b> , 76, 2650-2670	15
172	Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction. <b>2020</b> , 22, L124-L128	1
171	Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS 7.6 Post-Approval Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006863	51
170	Kidney Disease in the Cardiac Catheterization Laboratory. <b>2020</b> ,	
-(-		
169	Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations. <b>2020</b> , 16, 769-785	10
169		10
	(HFpEF): Current Perspectives and Recommendations. 2020, 16, 769-785  Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic	
168	(HFpEF): Current Perspectives and Recommendations. 2020, 16, 769-785  Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor. 2020, 14, 1  Increased frequency of occurrence of bendopnea is associated with poor outcomes in heart failure	1

## (2021-2020)

164	Independent and incremental prognostic value of semiquantitative measures of tricuspid regurgitation severity in heart failure with preserved ejection fraction. <b>2020</b> ,	4
163	Determination of optimal implantation site in central venous system for wireless hemodynamic monitoring. <b>2020</b> , 27, 100510	Ο
162	Obesity-Related Heart Failure with Preserved Ejection Fraction: Pathophysiology, Diagnosis, and Potential Therapies. <b>2020</b> , 16, 357-368	11
161	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. <b>2020</b> , 63, 570-584	22
160	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. <b>2020</b> , 36, 1148-1151	11
159	Right-sided cardiac disease: no longer the <b>Q</b> ark side of the heartQ <b>2020</b> , 22, 1226-1229	0
158	CardioMEMS System in the Daily Management of Heart Failure: Review of Current Data and Technique of Implantation. <b>2020</b> , 17, 637-648	4
157	: A New Section of Highlighting Invasive emodynamics. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006927 7.6	
156	Evaluation and management of heart failure with preserved ejection fraction. 2020, 17, 559-573	113
155	Acute heart failure. <b>2020</b> , 6, 16	70
155 154	Acute heart failure. 2020, 6, 16  Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). 2020, 22, 1891-1901	70 52
	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure:	52
154	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). <b>2020</b> , 22, 1891-1901	52
154 153	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). <b>2020</b> , 22, 1891-1901  Rationale and design of the CardioMEMS Post-Market Multinational Clinical Study: COAST. <b>2020</b> , 7, 865-872  Association of Implantable Device Measured Physical Activity With Hospitalization for	52
154 153 152	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). 2020, 22, 1891-1901  Rationale and design of the CardioMEMS Post-Market Multinational Clinical Study: COAST. 2020, 7, 865-872  Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. 2020, 8, 280-288  Lifestyle Modification or Medication to Improve Condition of Patients With Asymptomatic Heart Failure - Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization II	52 12 7
154 153 152 151	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). 2020, 22, 1891-1901  Rationale and design of the CardioMEMS Post-Market Multinational Clinical Study: COAST. 2020, 7, 865-872  Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. 2020, 8, 280-288  Lifestyle Modification or Medication to Improve Condition of Patients With Asymptomatic Heart Failure - Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization II (MOMOTARO II) Study. 2020, 84, 456-462  Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the	52 12 7
154 153 152 151 150	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). 2020, 22, 1891-1901  Rationale and design of the CardioMEMS Post-Market Multinational Clinical Study: COAST. 2020, 7, 865-872  Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. 2020, 8, 280-288  Lifestyle Modification or Medication to Improve Condition of Patients With Asymptomatic Heart Failure - Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization II (MOMOTARO II) Study. 2020, 84, 456-462  Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America. 2020, 26, 448-456  Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection	52 12 7 3 85

146	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. <b>2021</b> , 133, 125-139	3
145	Home Monitoring of Cardiac Devices in the Era of COVID-19. <b>2020</b> , 23, 1	13
144	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <b>2021</b> , 27, 2-19	5
143	Echo-Based Approach to the Management of Heart Failure With Preserved Ejection Fraction. <b>2021</b> , 473-488	
142	Letter by Mirwais et al Regarding Article, "Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure". 7.6 Circulation: Heart Failure, <b>2021</b> , 14, e007914	1
141	Visual echocardiographic scoring system of the left ventricular filling pressure and outcomes of heart failure with preserved ejection fraction. <b>2021</b> ,	O
140	Stage D Heart Failure With Preserved Ejection Fraction, Heart Transplantation, and Mechanical Circulatory Support. <b>2021</b> , 276-289	
139	Long Term Hemodynamic Monitoring. <b>2021</b> , 141-150	
138	Beyond the stethoscope: managing ambulatory heart failure during the COVID-19 pandemic. <b>2021</b> , 8, 999-1006	4
137	Korunmulejeksiyon fraksiyonlu kalp yetmezlil 94-97	
136	Remote monitoring in heart failure: current and emerging technologies in the context of the pandemic. <b>2021</b> , 107, 366-372	6
135	Wireless Hemodynamic Monitoring in Patients with Heart Failure. <b>2021</b> , 18, 12-22	3
134	New Hemodynamic Insights in Pulmonary Vascular Disease and Heart Failure with Preserved Ejection Fraction. <b>2021</b> , 23, 1	
133	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection 7.6	2
132	[Care of patients with chronic heart failure: an interdisciplinary challenge]. 2021, 146, 309-316	1
131	Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps. <b>2021</b> , 10, e017684	2
130	Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. <b>2021</b> , 9, 523	1
129	Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy. <b>2021</b> , 10, e017619	6

128	Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. <b>2021</b> , 143, 1673-1686	35
127	Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction. <b>2021</b> , 34, 455-464	О
126	The Vexing Problem of HFpEF Therapeutics: Inching Toward Success. <b>2021</b> , 9, 371-373	О
125	Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial. <b>2021</b> , 9, 360-370	16
124	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. <b>2021</b> , 39, 1522-1545	7
123	Liver Congestion Assessed by Hepatic Vein Waveforms in Patients With Heart Failure. <b>2021</b> , 3, 778-786	2
122	Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice: A Sex-Specific Analysis of the CardioMEMS Post-Approval Study. 7.6 Circulation: Heart Failure, <b>2021</b> , 14, e007892	2
121	Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides. <b>2021</b> , 8, 683418	2
120	Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis: Prognostic and Therapeutic Implications. <b>2021</b> , 17, 499-518	3
119	Early Increased Physical Activity, Cardiac Rehabilitation, and Survival After Implantable Cardioverter-Defibrillator Implantation. <b>2021</b> , 14, e007580	1
118	Novel Non-Pharmaceutical Advancements in Heart Failure Management: The Emerging Role of Technology. <b>2021</b> ,	
117	Heart-Lung Interaction and Its Prognostic Significance in Heart Failure Patients With Preserved Ejection Fraction. <b>2021</b> , 85, 1435-1437	
116	Pulmonary Hypertension in the Context of Heart Failure With Preserved Ejection Fraction. <b>2021</b> , 160, 2232-2246	1
115	Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. <b>2021</b> , 8, 3472-3482	5
114	Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. 2021,	6
113	Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction. <b>2021</b> , 6, 772-795	5
112	Advances in the management of pulmonary arterial hypertension. <b>2021</b> , 69, 1270-1280	4
111	Outcomes in Hospitalization in Patients with Heart Failure Undergoing Remote Pulmonary Artery Pressure Monitoring: A Systematic Review and Meta-Analysis of Major Trials. <b>2021</b> , 100980	О

14

A Single-center Experience of CardioMEMS in Patients With Left Ventricular Assist Devices. 2021, 110 Pulmonary Artery Pressure Monitoring Effectively Guides Management to Reduce Heart Failure 109 Hospitalizations in Obesity. 2021, 9, 784-794 Noncontrast Cardiac Magnetic Resonance Imaging Predictors of Heart Failure Hospitalization in 108 1 Heart Failure With Preserved Ejection Fraction. 2021, "House Calls" by Mobile Integrated Health Paramedics for Patients with Heart Failure: A Feasibility 107 Study. 2021, 1-9 Advanced Heart Failure in a Special Population: Heart Failure with Preserved Ejection Fraction. 106 0 **2021**. 17. 685-695 Right Heart Catheterization in Patients with Advanced Heart Failure: When to Perform? How to 105 Interpret?. 2021, 17, 647-660 Invasive Hemodynamic Assessment in Heart Failure With Preserved Ejection Fraction. 2021, 93-105 104 General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials. 2021, 463-472 103 Diuretic Resistance and Chronic Heart Failure. 2020, 121-135 102 1 Cardiac Implantable Electronic Devices. 2017, 285-294 101 Pulmonary hypertension in aortic valve stenosis. 2020, 100 2 Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary 99 artery pressure sensor: the new normal. 2020, 22, P29-P32 Telemonitoring and hemodynamic monitoring to reduce hospitalization rates in heart failure: a 98 systematic review and meta-analysis of randomized controlled trials and real-world studies. 2018, 13 15, 298-309 Recent advances in the treatment of chronic heart failure. 2019, 8, 97 2020 Clinical practice guidelines for Chronic heart failure. 2020, 25, 4083 96 95 Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, 95 and prognosis. **2020**, 53, e9646 Management of heart failure with preserved ejection fraction. 2020, 43, 12-17 94 2

93

CardioMEMS: where we are and where can we go?. 2019, 7, 418

92	Overview of WHO Group 2 Pulmonary Hypertension Due to Left Heart Disease. 2015, 14, 70-78	4
91	Heart failure with preserved ejection fraction: insights from recent clinical researches. <b>2020</b> , 35, 514-534	4
90	Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. 2020, 12, 7-25	16
89	Ambulatory pulmonary artery pressure monitoring in advanced heart failure patients. <b>2017</b> , 9, 21-26	8
88	In Search of Clinical Impact: Advanced Monitoring Technologies in Daily Heart Failure Care. <b>2021</b> , 10,	О
87	Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. <b>2021</b> , 12, 746494	8
86	Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction. 2021,	2
85	SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure-further evidence for improved hemodynamics by continuous pressure monitoring. <b>2021</b> , 111, 469	O
84	CardioMEMSIIa tool for remote hemodynamic monitoring of chronic heart failure patients. 2021,	3
83	Ambulatory Hemodynamic Monitoring of Pulmonary Hypertension. <b>2015</b> , 16, 154-164	
82	Current Technology to Maximize Cardiac Resynchronization Therapy Benefit for Patients With Symptomatic Heart Failure. <b>2015</b> , 26, 329-340	0
81	NEAT HFpEF: Organic nitrates fail to deliver. <b>2016</b> , 2016, e201601	1
80	Pulmonary Hypertension in Left Heart Disease. <b>2017</b> , 341-369	
79	Ambulatory Heart Failure Monitoring: A Systemic Review. <b>2017</b> , 9, e1174	5
78	CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: TREATMENT IN CONDITIONS OF LIMITED EVIDENCE. <b>2018</b> , 25, 106-114	
77	Battery-Free Wireless Sensors for Healthcare and Food Quality Monitoring. <b>2018</b> , 527-550	
76	Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future. <b>2020</b> , 114, 120-129	О

74	Hemodynamic Insights to Cardio-Renal Syndrome: A View Looking Back to See Forward. <b>2020</b> , 11-20	
73	[Diagnostics and treatment of chronic heart failure : Update 2020]. 2020, 1	
72	Heart Failure Drug Class Effects on 30-Day Readmission Rates in Patients with Heart Failure with Preserved Ejection Fraction: A Retrospective Single Center Study. <b>2020</b> , 7,	1
71	Non-Invasive Central Venous Pressure Measurement Using Enclosed-Zone Central Venous Pressure (ezCVP). <b>2020</b> , 84, 1112-1117	O
70	Modern view on heart failure with preserved ejection fraction. <b>2020</b> , 14-19	
69	Telemedizin bei Herzinsuffizienz. <b>2021</b> , 281-298	
68	Feasibility and safety of a telemetric pulmonary artery pressure monitoring system in acute and chronic porcine models of pulmonary hypertension.	
67	Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?. <b>2021</b> , 36, 211-218	
66	Traditional and Novel Invasive Hemodynamic Indices in the Evaluation of Congestive Heart Failure in Cardiorenal Syndrome. <b>2020</b> , 379-395	
65	Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?. <b>2020</b> , 12, e7323	
64	[Problematic aspects of pulmonary hypertension due to left heart disease: focus on combined postcapillary and precapillary pulmonary hypertension]. <b>2020</b> , 92, 54-62	2
63	Risk Marker Fatigue-Is There an Actionable Outcome?. <b>2021</b> , 6, 78	
62	Methods to Assess Intra- and Extravascular Volume Status in Heart Failure Patients. <b>2021</b> , 177-206	
61	The future of left ventricular assist devices. <b>2015</b> , 7, 2188-93	11
60	Transcatheter Implantable Devices to Monitoring of Elevated Left Atrial Pressures in Patients with Chronic Heart Failure. <b>2017</b> , 17, 19-21	4
59	Heart failure with preserved ejection fraction in the elderly: pathophysiology, diagnostic and therapeutic approach. <b>2019</b> , 16, 421-428	6
58	Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives. <b>2019</b> , 9, 91-108	6
57	Heart failure in the elderly. <b>2021</b> , 18, 219-232	1

56	[Remote invasive monitoring of pulmonary artery pressures in heart failure patients: Initial experience in Portugal in the context of the Covid-19 pandemic]. <b>2021</b> ,	2
55	Implantable cardiovascular devices: current and emerging technologies for remote heart failure monitoring 2022,	
54	Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure. <b>2022</b> , 4, 12	
53	HeartLogic: Ready for Prime Time?. <b>2022</b> ,	O
52	Heart Failure with Preserved Ejection Fraction. <b>2022</b> , 267-287	
51	Right atrial pressure represents cumulative cardiac burden in heart failure with preserved ejection fraction <b>2022</b> ,	1
50	Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary 7 Arterial Hypertension With Similar Pressure Overload Circulation: Heart Failure, <b>2021</b> , CIRCHEARTFAILUI	7.6 2 RE121008726
49	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <b>2022</b> , 101161CIR00000000000001063	35
48	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines <b>2022</b> ,	49
47	Medical management of acute heart failure <b>2021</b> , 10, 82	3
46	Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications <b>2022</b> ,	О
45	Clinical Profile-Based Pharmacological Sequencing for Heart Failure with Preserved Ejection Fraction. <b>2022</b> , 2, 72-75	
44	Essential Therapy for Heart Failure with Preserved Ejection Fraction in 2022. <b>2022</b> , 2, 55-63	
43	Restructuring the Heart From Failure to Success: Role of Structural Interventions in the Realm of Heart Failure <b>2022</b> , 9, 839483	
42	Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials <b>2022</b> ,	О
41	Highlights from the Transcatheter Cardiovascular Therapeutics 2021 meeting 2022,	
40	The Cardiorenal Syndrome in Heart Failure <b>2022</b> , 40, 219-235	О
39	When Pulmonary Hypertension Complicates Heart Failure <b>2022</b> , 40, 191-198	O

38	Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future <b>2022</b> , 24, 235	0
37	Implantable Hemodynamic Monitoring Systems. <b>2022,</b> 708-712	
36	Interactive remote patient monitoring devices for managing chronic health conditions: systematic review and meta-analysis (Preprint).	1
35	Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial.	1
34	Current updates in the pharmacotherapy of heart failure with a preserved ejection fraction. <b>2022</b> , 22,	
33	Reshaping Treatment of Heart Failure with Preserved Ejection Fraction. 2022, 11, 3706	
32	Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach. 13,	0
31	Diurnal variation of pulmonary artery pressure in ambulatory heart failure patients. 1-4	1
30	Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis.	2
29	An artificial intelligence-based noninvasive solution to estimate pulmonary artery pressure. 9,	
28	Novidades e Reflexës sobre o Tratamento Farmacolÿico da Insuficiïicia Cardïica com Frab de Ejeb Preservada. <b>2022</b> ,	0
27	Current Management of Heart Failure with Preserved Ejection Fraction. <b>2022</b> , 31, 166-178	O
26	Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. 2022, 40, 473-489	1
25	Epidemiology, Diagnosis, Pathophysiology, and Initial Approach to Heart Failure with Preserved Ejection Fraction. <b>2022</b> , 40, 397-413	1
24	Key Phenotypes of Heart Failure with Preserved Ejection Fraction. <b>2022</b> , 40, 415-429	0
23	Hemodynamically-Guided Management of Heart Failure Across the Ejection Fraction Spectrum. <b>2022</b> ,	0
22	Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials.	1
21	Left atrial dysfunction as the major driver of heart failure with preserved ejection fraction syndrome. <b>2022</b> , 50, 1073-1083	O

20	The Pressure for Progress in Heart Failure. <b>2022</b> ,	О
19	Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction.	Ο
18	Flowchart for Treatment of Heart Failure with Preserved Ejection Fraction. 2022, 2, 299-303	О
17	Reduction in 90'day readmission rates utilizing ambulatory pulmonary pressure monitoring.	Ο
16	Ambulatory pulmonary artery pressure monitoring reduces costs and improves outcomes in symptomatic heart failure: a single center Canadian experience. <b>2022</b> ,	О
15	Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?.	1
14	Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. heartjnl-2022-321885	0
13	Recent Advances in Remote Pulmonary Artery Pressure Monitoring for Patients with Chronic Heart Failure: Current Evidence and Future Perspectives. <b>2023</b> , 23, 1364	Ο
12	Heart Failure Case Studies. <b>2023</b> , 309-328	Ο
11	Prevention Supersedes Prediction of Worsening Heart Failure. 2023, 11, 157-160	Ο
10	Feasibility of tele-guided patient-administered lung ultrasound in heart failure. 2023, 15,	O
9	Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety. <b>2023</b> ,	Ο
8	Heart Failure With Preserved Ejection Fraction. 2023, 329, 827	O
7	Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non-invasive echocardiographic study.	O
6	Determinants of prognosis and management of patients with pulmonary hypertension due to left heart disease: a systematic review. <b>2023</b> , 28, 5115	О
5	Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology. <b>2023</b> , 147,	1
4	Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology. <b>2023</b> , 81, 1524-1542	О
3	Heart Failure with Preserved Ejection Fraction. <b>2023</b> , 89-106	Ο

2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. **2023**,

О

Heart Failure With Preserved Ejection Fraction. 2023,

О